Stock comparison
Haemonetics
BeOne Medicines
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
HAE
Haemonetics
Market cap
$2.98B
Sector
Healthcare
ONC
BeOne Medicines
Market cap
$33.15B
Sector
Healthcare
Overall winner
BeOne Medicines ONC
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | HAE | ONC | Winner |
|---|---|---|---|
| Warren Buffett | 70B | 62D | HAE |
| Benjamin Graham | 85A | 75D | HAE |
| Philip Fisher | 60C | 84C | ONC |
| Peter Lynch | 54C | 75B | ONC |
| Joel Greenblatt | 31F | 49D | ONC |
| Charlie Munger | 54D | 56D | ONC |
| Terry Smith | 55D | 60D | ONC |
Side-by-side metrics
| Metric | HAE | ONC |
|---|---|---|
| Market cap | $2.98B | $33.15B |
| P/E (TTM) | 24.8x | 107.5x |
| EV/EBIT | 14.1x | 28.9x |
| ROIC (TTM) | 8.37% | 7.73% |
| Gross margin | 55.74% | 87.17% |
| Net margin | 7.29% | 8.93% |
| Revenue CAGR 5y | 7.65% | 45.99% |
| EPS CAGR 5y | 24.62% | 67.36% |
| Debt / Equity | 1.5x | 0.4x |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
HAE leads on
- P/E (TTM)24.8xvs 107.5x+77%
- EV/EBIT14.1xvs 28.9x+51%
- ROIC (TTM)8.37%vs 7.73%+8%
ONC leads on
- Market cap$33.15Bvs $2.98B+91%
- Revenue CAGR 5y45.99%vs 7.65%+83%
- Debt / Equity0.4xvs 1.5x+72%
- EPS CAGR 5y67.36%vs 24.62%+63%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.